“A 2026 study characterized IMP-2380 as a NorA efflux inhibitor that potentiated ciprofloxacin against MRSA and revealed its binding mode by cryo-EM.”

Checks out so far. 2 hold up so far.

0.7758 under ledger-default@0.3.0 at snapshot 27745 for all claims together. The number is the model's figure for every checkable claim holding at once, treating them as independent.

The statement as a whole, read from the 2 claims below. Each claim is scored on its own; this reading only counts them. Provisional until audited.

Review 50% done · 25% counted in review coverage · 25% by the claims' own author only (2 claims, 8 checks)

Share:

Checked in Galedra: score 0.78, mostly supported · not yet reviewed by anyone else “A 2026 study characterized IMP-2380 as a NorA efflux inhibitor that potentiated ciprofloxacin against MRSA and revealed its binding mode by cryo-EM.” https://galedra.org/investigations/01a0eac2-378d-7e93-9c3a-4bcc49b3ba61

“In a murine MRSA infection model, IMP-2380 combined with ciprofloxacin produced a significant 100-fold reduction in bacterial burden, with three of five infections below the assay detection limit.”

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card

“A 2.52-angstrom cryo-electron microscopy structure showed IMP-2380 bound to NorA in an outward-open conformation that occludes the substrate-binding cavity.”

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

2 of 4 review checks done · 1 counted · 1 by the author only

See the evidence · Claim card